Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-16 · accession 0000899243-23-005565 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-17 | 2023-02-16 | WVE | Vargeese Chandra | See Remarks | S - Sale | $4.03 | -10.2K | 106.6K | -9% | -$41.3K |
| D | 2023-02-17 | 2023-02-17 | WVE | Vargeese Chandra | See Remarks | A - Grant | $0.00 | +295.4K | 295.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-02-16 | S | D | 10,249 | $4.03 | 106,624 | D | — | — | (F2) The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.17 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. (F3) Includes 1,500 ordinary shares acquired on July 14, 2022, and 4,278 ordinary shares acquired on January 14, 2023, under the issuer's 2019 Employee Share Purchase Plan. |
| 2 | Derivative | Share Option (right to buy) | 2023-02-17 | A | A | 295,400 | $0.00 | 295,400 | D | $4.75 · — to 2033-02-17 | 295,400 Ordinary Shares | (F4) The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. |